Alessandra Tosolini

3.6k total citations
28 papers, 1.2k citations indexed

About

Alessandra Tosolini is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Alessandra Tosolini has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Hematology. Recurrent topics in Alessandra Tosolini's work include Acute Myeloid Leukemia Research (9 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Genomic variations and chromosomal abnormalities (4 papers). Alessandra Tosolini is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Genomic variations and chromosomal abnormalities (4 papers). Alessandra Tosolini collaborates with scholars based in United States, France and Italy. Alessandra Tosolini's co-authors include Joseph R. Testa, Michele Carbone, Paola Rizzo, Maurizio Bocchetta, Harvey I. Pass, Gary D. Kruh, Martin G. Belinsky, Hao Zeng, Amy Powers and Raoul Fresco and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Alessandra Tosolini

26 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alessandra Tosolini United States 16 570 387 338 206 136 28 1.2k
Ravindran Ankathil Malaysia 22 649 1.1× 318 0.8× 225 0.7× 94 0.5× 251 1.8× 99 1.3k
Noriko Fukuhara Japan 21 424 0.7× 390 1.0× 317 0.9× 91 0.4× 104 0.8× 152 1.5k
Rosa Di Noto Italy 21 517 0.9× 207 0.5× 377 1.1× 61 0.3× 97 0.7× 43 1.1k
Tamara I. Pestina United States 20 460 0.8× 155 0.4× 489 1.4× 81 0.4× 62 0.5× 32 1.1k
José Perdomo Australia 16 711 1.2× 155 0.4× 369 1.1× 102 0.5× 78 0.6× 39 1.4k
Tomoko Hata Japan 22 387 0.7× 156 0.4× 326 1.0× 64 0.3× 63 0.5× 96 1.5k
Thomas S. K. Wan Hong Kong 19 630 1.1× 226 0.6× 194 0.6× 75 0.4× 276 2.0× 56 1.1k
Alexandros Spyridonidis Greece 20 281 0.5× 272 0.7× 594 1.8× 52 0.3× 69 0.5× 75 1.1k
Olivier Spertini Switzerland 15 378 0.7× 205 0.5× 249 0.7× 77 0.4× 132 1.0× 51 1.4k

Countries citing papers authored by Alessandra Tosolini

Since Specialization
Citations

This map shows the geographic impact of Alessandra Tosolini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandra Tosolini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandra Tosolini more than expected).

Fields of papers citing papers by Alessandra Tosolini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandra Tosolini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandra Tosolini. The network helps show where Alessandra Tosolini may publish in the future.

Co-authorship network of co-authors of Alessandra Tosolini

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandra Tosolini. A scholar is included among the top collaborators of Alessandra Tosolini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandra Tosolini. Alessandra Tosolini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Daver, Naval, Naveen Pemmaraju, Mikkael A. Sekeres, et al.. (2024). Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy. Blood. 144(Supplement 1). 4265.1–4265.1. 1 indexed citations
3.
Kalaitzaki, Eleftheria, Shuai Yuan, Alessandra Tosolini, et al.. (2023). Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis. Clinical Lymphoma Myeloma & Leukemia. 23(5). e213–e221. 9 indexed citations
4.
Stein, Eytan M., Amir T. Fathi, Courtney D. DiNardo, et al.. (2020). Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. The Lancet Haematology. 7(4). e309–e319. 79 indexed citations
5.
Pollyea, Daniel A., Martin S. Tallman, Stéphane de Botton, et al.. (2019). Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 33(11). 2575–2584. 165 indexed citations
6.
7.
Pollyea, Daniel A., Martin S. Tallman, Stéphane de Botton, et al.. (2017). Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2) Acute Myeloid Leukemia (AML). Blood. 130(Suppl_1). 638–638. 13 indexed citations
8.
Gupta, Shilpa, Guillem Argilés, Pamela N. Münster, et al.. (2015). A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clinical Cancer Research. 21(23). 5235–5244. 27 indexed citations
9.
10.
Piha‐Paul, Sarina A., P.N. Munster, Antoine Hollebecque, et al.. (2015). Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. European Journal of Cancer. 51(14). 1865–1873. 63 indexed citations
11.
Kirschbaum, Mark, Ivana Gojo, Stuart L. Goldberg, et al.. (2014). A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. British Journal of Haematology. 167(2). 185–193. 96 indexed citations
12.
Gupta, Supriya, Antoine Hollebecque, Guillem Argilés, et al.. (2014). Safety and Efficacy of MK-8669 (Ridaforolimus) + MK-2206 (AKT Inhibitor) in Patients with Advanced Breast Cancer with PI3K Pathway Dependence. Annals of Oncology. 25. i25–i25. 1 indexed citations
13.
14.
Zollino, Marcella, Cesare Colosimo, Orsetta Zuffardi, et al.. (2002). Cryptic t(1;12)(q44;p13.3) translocation in a previously described syndrome with polymicrogyria, segregating as an apparently X‐linked trait. American Journal of Medical Genetics Part A. 117A(1). 65–71. 17 indexed citations
15.
Park, Brian, Nhan Trung Nguyen, Parmesh Dutt, et al.. (2002). Association of Lbc Rho Guanine Nucleotide Exchange Factor with α-Catenin-related Protein, α-Catulin/CTNNAL1, Supports Serum Response Factor Activation. Journal of Biological Chemistry. 277(47). 45361–45370. 52 indexed citations
16.
Foddis, Rudy, Assunta De Rienzo, Dominique Broccoli, et al.. (2002). SV40 infection induces telomerase activity in human mesothelial cells. Oncogene. 21(9). 1434–1442. 91 indexed citations
17.
Belinsky, Martin G., et al.. (2001). Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Letters. 162(2). 181–191. 148 indexed citations
18.
Balsara, Binaifer, Jianming Pei, Assunta De Rienzo, et al.. (2001). Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes and Cancer. 30(3). 245–253. 58 indexed citations
19.
Bocchetta, Maurizio, Ilaria Di Resta, Amy Powers, et al.. (2000). Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proceedings of the National Academy of Sciences. 97(18). 10214–10219. 181 indexed citations
20.
Tosolini, Alessandra, et al.. (2000). Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenetic and Genome Research. 88(1-2). 38–40. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ravindran Ankathil Breakdown of academic impact, for papers by Noriko Fukuhara Breakdown of academic impact, for papers by Rosa Di Noto Breakdown of academic impact, for papers by Tamara I. Pestina Breakdown of academic impact, for papers by José Perdomo Breakdown of academic impact, for papers by Tomoko Hata Breakdown of academic impact, for papers by Thomas S. K. Wan Breakdown of academic impact, for papers by Alexandros Spyridonidis Breakdown of academic impact, for papers by Olivier Spertini
Rankless by CCL
2026